JAZZ - CIK 0001232524
Jazz Pharmaceuticals plc trades as JAZZ and has a market capitalization of $14.41 B, making it the #749 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $4.27B, up 4.9% from the prior year and net income of -$356.15M. This page tracks Jazz Pharmaceuticals plc through 2,093 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Jazz Pharmaceuticals plc's revenue grew from $1.49B to $4.27B, a compound annual growth rate of 12.4%. Net profit margin compressed from 26.7% to -8.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-22 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider sale notice | 144 | 2026-05-01 |
| SCHEDULE 13G | - | 2026-04-30 |
| Annual report (amended) | 10-K/A | 2026-04-24 |
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Jazz Pharmaceuticals plc
None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results | Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Jazz Pharmaceuticals plc
The largest companies sharing Jazz Pharmaceuticals plc's SEC industry classification (pharmaceutical preparations).
Jazz Pharmaceuticals plc (JAZZ) has a market capitalization of $14.41 B as of 2026-06-10, ranking #749 among US-listed companies.
Jazz Pharmaceuticals plc reported revenue of $4.27B for fiscal year 2025, an increase of 4.9% year over year.
In its latest fiscal year Jazz Pharmaceuticals plc reported a net loss of $356.15M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.